Analysts have been eager to weigh in on the Healthcare sector with new ratings on CymaBay Therapeutics (CBAY) and Ascendis Pharma (ASND).
CymaBay Therapeutics (CBAY)
CymaBay Therapeutics received a Buy rating and an $8.00 price target from JonesTrading analyst Prakhar Agrawal today. The company’s shares closed last Friday at $4.68.
According to TipRanks.com, Agrawal is a 1-star analyst with an average return of -2.7% and a 45.8% success rate. Agrawal covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Phathom Pharmaceuticals, and Aldeyra Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CymaBay Therapeutics with a $11.22 average price target, representing a 140.6% upside. In a report issued on June 9, Piper Sandler also maintained a Buy rating on the stock with a $12.00 price target.
See today’s analyst top recommended stocks >>
Ascendis Pharma (ASND)
In a report released today, Leland Gershell from Oppenheimer maintained a Hold rating on Ascendis Pharma. The company’s shares closed last Friday at $130.25.
According to TipRanks.com, Gershell is a 4-star analyst with an average return of 8.7% and a 42.2% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $190.57.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
